23andMe Holding Co (23andMe Holding Co) GF Score : 34/100 (As of May. 17, 2024)

View and export this data going back to 2021. Start your Free Trial

What is 23andMe Holding Co GF Score?

23andMe Holding Co has the GF Score of 34, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 4/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 4/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes 23andMe Holding Co might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of 23andMe Holding Co's GF Score

For the Diagnostics & Research subindustry, 23andMe Holding Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

23andMe Holding Co's GF Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, 23andMe Holding Co's GF Score distribution charts can be found below:

* The bar in red indicates where 23andMe Holding Co's GF Score falls into.

23andMe Holding Co (NAS:ME) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

23andMe Holding Co GF Score Related Terms

Thank you for viewing the detailed overview of 23andMe Holding Co's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

23andMe Holding Co (23andMe Holding Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » 23andMe Holding Co (NAS:ME) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

349 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.23andme.com

23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment include Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.

Executives

Kathy L Hibbs	officer: See Remarks	C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
William G Richards	officer: Head of Therapeutics Discovery	160 KELLY AVE, HALF MOON BAY CA 94019
Richard H Scheller	director	C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Joseph Anthony Selsavage	officer: Interim CFO	490 HILL STREET, APT 5, SAN FRANCISCO CA 94114
Kenneth J. Hillan	officer: Head of Therapeutics	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Evan Lovell	director, officer: Chief Financial Officer	27 SOUTH PARK STREET, SUITE 200, SAN FRANCISCO CA 94107
Hernandez Sandra R Md	director	BLACKBAUD INC, 2000 DANIEL ISLAND DRIVE, CHARLESTON SC 29492
Paul D Johnson	officer: VP, General Manager-Consumer	440 N BARRANCA AVE #3550, COVINA CA 91723
Tracy Keim	officer: See Remarks	6107 ARROWROOT LANE, RANCHO PALOS VERDES CA 90275
Steven Lemon	officer: Vice President, Engineering	1020 CHERRY AVENUE, SAN JOSE CA 95125
Steven J Schoch	officer: See Remarks	2748 BUSH STREET, SAN FRANCISCO CA 94115
Frederick Mark Kohler	officer: Vice President, People	1004 UNION STREET, ALAMEDA CA 94501
Sequoia Capital Global Growth Ii Principals Fund, L.p.	10 percent owner	2800 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Abeec 2.0, Llc	10 percent owner	171 MAIN STREET, SUITE 259, LOS ALTOS CA 94022
Anne Wojcicki	director, 10 percent owner, officer: Chief Executive Officer	C/O AJAX I HOLDINGS, LLC, 667 MADISON AVENUE, NEW YORK NY 10606